ABIONYX PHARMA SA (ABNX.PA) Stock Price & Overview
EPA:ABNX • FR0012616852
Current stock price
The current stock price of ABNX.PA is 3.495 EUR. Today ABNX.PA is down by -2.92%. In the past month the price increased by 7.62%. In the past year, price increased by 210.35%.
ABNX.PA Key Statistics
- Market Cap
- 124.107M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.16
- Dividend Yield
- N/A
ABNX.PA Stock Performance
ABNX.PA Stock Chart
ABNX.PA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 98.56% of all stocks.
ABNX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ABNX.PA. ABNX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ABNX.PA Earnings
ABNX.PA Forecast & Estimates
8 analysts have analysed ABNX.PA and the average price target is 10.71 EUR. This implies a price increase of 206.44% is expected in the next year compared to the current price of 3.495.
ABNX.PA Groups
Sector & Classification
ABNX.PA Financial Highlights
Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS decreased by -22.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.32% | ||
| ROE | -123.01% | ||
| Debt/Equity | 0.67 |
ABNX.PA Ownership
ABNX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 29.29 | 42.202B | ||
| 1AE | ARGENX SE | 29.42 | 42.19B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.117B | ||
| ABVX | ABIVAX SA | N/A | 8.555B | ||
| 2X1 | ABIVAX SA | N/A | 8.555B | ||
| GLPG | GALAPAGOS NV | N/A | 1.608B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.238B | ||
| PHARM | PHARMING GROUP NV | 48.55 | 1.036B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.007B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 975.338M | ||
| PHGN | PHARMING GROUP NV | 45.96 | 975.297M | ||
| IVA | INVENTIVA SA | N/A | 939.888M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ABNX.PA
Company Profile
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Company Info
IPO: 2015-03-30
ABIONYX PHARMA SA
Bat. D 33-43 Avenue Georges Pompidou
Balma OCCITANIE FR
Employees: 51
Phone: 33562249706
ABIONYX PHARMA SA / ABNX.PA FAQ
What does ABIONYX PHARMA SA do?
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
What is the current price of ABNX stock?
The current stock price of ABNX.PA is 3.495 EUR. The price decreased by -2.92% in the last trading session.
Does ABIONYX PHARMA SA pay dividends?
ABNX.PA does not pay a dividend.
How is the ChartMill rating for ABIONYX PHARMA SA?
ABNX.PA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ABNX.PA stock?
8 analysts have analysed ABNX.PA and the average price target is 10.71 EUR. This implies a price increase of 206.44% is expected in the next year compared to the current price of 3.495.
Can you provide the sector and industry classification for ABIONYX PHARMA SA?
ABIONYX PHARMA SA (ABNX.PA) operates in the Health Care sector and the Biotechnology industry.
How many employees does ABIONYX PHARMA SA have?
ABIONYX PHARMA SA (ABNX.PA) currently has 51 employees.